GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (TSX:ONC) » Definitions » E10

Oncolytics Biotech (TSX:ONC) E10 : C$-1.00 (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Oncolytics Biotech E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Oncolytics Biotech's adjusted earnings per share data for the three months ended in Dec. 2024 was C$-0.100. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is C$-1.00 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average E10 Growth Rate was 18.20% per year. During the past 5 years, the average E10 Growth Rate was 17.30% per year. During the past 10 years, the average E10 Growth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Oncolytics Biotech was 18.20% per year. The lowest was -57.10% per year. And the median was 2.70% per year.

As of today (2025-03-17), Oncolytics Biotech's current stock price is C$0.91. Oncolytics Biotech's E10 for the quarter that ended in Dec. 2024 was C$-1.00. Oncolytics Biotech's Shiller PE Ratio of today is .


Oncolytics Biotech E10 Historical Data

The historical data trend for Oncolytics Biotech's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech E10 Chart

Oncolytics Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.15 -1.83 -1.43 -1.18 -1.00

Oncolytics Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.18 -1.13 -1.09 -1.04 -1.00

Competitive Comparison of Oncolytics Biotech's E10

For the Biotechnology subindustry, Oncolytics Biotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Shiller PE Ratio falls into.



Oncolytics Biotech E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncolytics Biotech's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.1/127.3637*127.3637
=-0.100

Current CPI (Dec. 2024) = 127.3637.

Oncolytics Biotech Quarterly Data

per share eps CPI Adj_EPS
201503 -0.380 99.789 -0.485
201506 -0.285 100.500 -0.361
201509 -0.190 100.421 -0.241
201512 -0.285 99.947 -0.363
201603 -0.285 101.054 -0.359
201606 -0.190 102.002 -0.237
201609 -0.285 101.765 -0.357
201612 -0.440 101.449 -0.552
201703 -0.285 102.634 -0.354
201706 -0.320 103.029 -0.396
201709 -0.200 103.345 -0.246
201712 -0.320 103.345 -0.394
201803 -0.310 105.004 -0.376
201806 -0.270 105.557 -0.326
201809 -0.200 105.636 -0.241
201812 -0.280 105.399 -0.338
201903 -0.270 106.979 -0.321
201906 -0.260 107.690 -0.307
201909 -0.160 107.611 -0.189
201912 -0.830 107.769 -0.981
202003 -0.040 107.927 -0.047
202006 -0.170 108.401 -0.200
202009 -0.160 108.164 -0.188
202012 -0.220 108.559 -0.258
202103 -0.130 110.298 -0.150
202106 -0.130 111.720 -0.148
202109 -0.090 112.905 -0.102
202112 -0.140 113.774 -0.157
202203 -0.120 117.646 -0.130
202206 -0.090 120.806 -0.095
202209 -0.080 120.648 -0.084
202212 -0.150 120.964 -0.158
202303 -0.100 122.702 -0.104
202306 -0.120 124.203 -0.123
202309 -0.140 125.230 -0.142
202312 -0.050 125.072 -0.051
202403 -0.090 126.258 -0.091
202406 -0.100 127.522 -0.100
202409 -0.120 127.285 -0.120
202412 -0.100 127.364 -0.100

Add all the adjusted EPS together and divide 10 will get our e10.


Oncolytics Biotech  (TSX:ONC) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Oncolytics Biotech E10 Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
Executives
Angela Frances Holtham Director
Deborah Brown Director
Bernd Robert Seizinger Director
Matthew Coffey Director, Senior Officer
Kirk Look Senior Officer